

10/04/02

1644

Patent
032077.0002.UTL1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 08 2002

In re the Application of:

Applicant: Daniel P. Gold

Serial No.: 09/927,122

Filed: August 10, 2001

For: METHOD AND COMPOSITION
FOR ALTERING A T CELL MEDIATED
PATHOLOGY

Group Art Unit: 1644

Examiner: Amy M. Decloux

TECH CENTER 1600/2900

p#11

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed are the following documents:

- Supplemental Information Disclosure Statement;
- Form PTO/SB/08A;
- Copies of cited references;
- Copy of International Search Report; and
- Return Postcard.

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Oct. 2, 2002
Date of Deposit


Megan Massey
Name of Person Mailing Paper
Megan Massey
Signature of Person Mailing Paper

No fee is believed due with this submission; however, the Commissioner is authorized to charge any fee required, or to credit any overpayment, to our Deposit Account No. **50-1273**.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated: 10/2/02

By: 
Jeffrey W. Guise
Reg. No. 34,613

DCM:mam

BROBECK, PHLEGER & HARRISON LLP

12390 El Camino Real
San Diego, CA 92130-2081
Phone: (858) 720-2500
Fax: (858) 720-2555



Patent
032077.0002.UTL1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Daniel P. Gold

Serial No.: 09/921,122

Filed: August 10, 2001

**For: METHOD AND COMPOSITION
FOR ALTERING A T CELL MEDIATED
PATHOLOGY**

Group Art Unit: 1644

Examiner: Amy M. Decloux

RECEIVED

OCT 08 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.56, the following information is brought to the attention of the Examiner. The item is listed on the attached Form PTO/SB/08A and a copy is enclosed for the convenience of the Examiner. Applicants respectfully request that the document be made of record in the above-referenced application.

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Oct. 2, 2002
Date of Deposit

Megan Massey
Name of Person Mailing Paper
Megan Massey
Signature of Person Mailing Paper


The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.


The attached Information Disclosure Statement is being filed in accordance with 37 CFR 1.97 and 1.98. This Information Disclosure Statement is believed to be timely in that it is being submitted under 37 CFR 1.97(b)(3), that is before the mailing of a first Office Action on the merits. Thus, no petition or fee is required. However, if the undersigned representative of Applicant is in error in this regard, then the Examiner is requested to consider this Information Disclosure Statement as filed under 1.97(c) with the following statement under 1.97(e)(1): That each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Dated: 10/2/02

By: 
Jeffrey W. Guise
Reg No. 34,613

BROBECK, PHLEGER & HARRISON LLP
12390 El Camino Real
San Diego, CA 92130-2081
Phone: (858) 720-2500
Fax: (858) 720-2555



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	032077.0002.UTL1
		Filing Date	August 10, 2001
		First Named Inventor	Gold, Daniel P.
		Group Art Unit	1644
		Examiner Name	Amy M. Decloux
Sheet 1 of 1	Attorney Docket Number	032077.0002.UTL1	

RECEIVED

OCT 08 2002

TECH CENTER 600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
	AA	WO	99/18129		Weidanz, J., et al.	04-15-1999
	AB	WO	01/93913		Weidanz, J., et al.	12-13-2001
	AC	WO	00/31239		Bolhuis, R.	06-02-2000

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AD	Jesson, M., et al., "The Immune Response to Soluble D10 TCR: Analysis of Antibody and T Cell Responses," <i>International Immunology</i> , 1(10), pg. 27-35 (1998)	
	AE	Jesson, M., et al., "Immunogenicity of Recombinant, Soluble Cell Receptors in Syngeneic Mice," <i>International Congress of Immunology Abstracts</i> , pg. 442 (1995)	
	AF	Wong, C., et al., "Recombinant Adenovirus Vaccine Encoding a Chimeric T-Cell Antigen Receptor Induces Protective Immunity Against a T-Cell Lymphoma," <i>Cancer Research</i> , 10 (60), pg. 2689-2695 (2000)	
	AG	Gascoigne, N., et al., "Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein," <i>Proceedings of the National Academy of Sciences of USA</i> , 84 (9), pg. 2936-2940 (1987)	
	AH	Vandenbark, A., et al., "T-Cell Receptor Peptides in Treatment of Autoimmune Disease: Rationale and Potential," <i>Journal of Neuroscience Research</i> , 43 (4), pg. 391-402 (1996)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.